The Babak Lab shared a post on LinkedIn about a recent article by Eileen O’Reilly et al., published in The New England Journal of Medicine:
“Daraxonrasib confirms phase 3 benefit in pancreatic cancer
A few weeks ago, we covered the phase 1/2 RMC-6236-001 study, where daraxonrasib showed promising activity in previously treated pancreatic cancer. Now, the phase 3 RASolute 302 trial confirms those early signals in a randomized study.
Key Insights
- RASolute 302 enrolled ≈500 patients, 91.8% with RAS G12 mutations, with previously treated mPDAC and compared daraxonrasib with investigator’s choice chemotherapy
- mOS doubled: 13.2 months with daraxonrasib vs 6.7 months with chemotherapy | HR: 0.40
- mPFS also doubled: 7.2 months with daraxonrasib vs 3.6 months with chemotherapy | HR: 0.49
- Daraxonrasib was generally well tolerated and showed fewer severe adverse events than chemotherapy
Conclusion
RASolute 302 now provides phase 3 evidence that treatment with daraxonrasib leads to significantly longer overall survival and progression-free survival than chemotherapy among patients with previously treated mPDAC. This marks one of the most significant advances in metastatic pancreatic cancer in decades.
Image generated using Sora by OpenAI.”
Title: Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer
Authors: Eileen O’Reilly, Zev Wainberg, Andrew Hendifar, Mitesh Borad, Filippo Pietrantonio, Shubham Pant, Pascal Hammel, Chiara Cremolini, Gulam Manji, Paul Oberstein, Ignacio Garrido-Laguna, Christoph Springfeld, Nilofer Azad, Makoto Ueno, Stephen Chui, Ying Zhang, Hina Patel, Yeonju Lee, Zeena Salman, Brian Wolpin
Read the Full Article on The New England Journal of Medicine
Maria Babak, Head of the Babak Lab and Assistant Professor at City University of Hong Kong, shared this post, adding:
“A genuinely landmark moment: doubled OS and PFS in previously treated mPDAC. Joining the standing ovation!”
More posts about The Babak Lab.